Condition
HTLV-I Infection
Total Trials
5
Recruiting
1
Active
1
Completed
4
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
25%
1 of 4 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
3Total
Early P 1 (1)
P 1 (1)
P 2 (1)
Trial Status
Completed4
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT00001778RecruitingPrimary
Evaluation of Patients With HAM/TSP
NCT01867320Early Phase 1CompletedPrimary
Raltegravir for HAM/TSP
NCT00001156Completed
Assessment of Patients With Multiple Sclerosis (MS)
NCT00001941Phase 1CompletedPrimary
Anti-Tac for Treatment of Leukemia
NCT00001785Phase 2CompletedPrimary
Recombinant Human Interferon Beta-1a (Avonex) for the Treatment of Patients With HTLV-1-Associated Myelopathy (HAM)
Showing all 5 trials